Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody

Lieberman, Gidon; Buscombe, J. R.; Hilson, A. J.W.; Reid, Wendy; Thakrar, D. S.; MacLean, Allan

doi:10.1067/mob.2000.105938

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioimmunoscintigraphy revealed the presence of disease in 36 out of 41 patients with carcinona of the ovaries, corresponding to an overall sensitivity of 41%, while speci city was 42% and accuracy 83%. Similar results were reported in another study with 18 patients (59). All primary malignancies yielded positive results on radioimmunoscintigraphy, while serosal deposits that were not detected on CT or ultrasound were revealed with the radiolabeled MoAb.…”

Section: Radioimmunodetectio N Of Ovarian Cancersupporting

confidence: 89%

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Kalofonos

2001

Acta Oncologica

View full text Add to dashboard Cite

The use of radiolabeled monoclonal antibodies (MoAbs) has significantly improved the ability to detect tumor antigens, thus improving in vivo tumor diagnosis and treatment. The management of ovarian carcinoma still poses a challenging medical problem. Clinical trials using radioimmunoscintigraphy or a hand-held gamma detection probe intraoperatively were performed in patients with clinical evidence of primary or recurrent ovarian cancer. Immunoscintigraphy of ovarian cancer lesions has been performed mainly with 99mTc, 111In and 123I labeled with HMFG1, HMFG2, OC-125, B72.3, H17E2, OVTL3, MoAb170, Mov18 and other MoAbs. Antibody guided imaging using radioimmunoscintigraphy has demonstrated improved targeting of ovarian cancer, resulting in a highly sensitive and specific method. However, it is not yet known which type of MoAb is the most efficient for radioimmunoscintigraphy. Since these tumors represent a potentially curable disease, radioimmunoscintigraphy could contribute mainly to accurate staging as a supplementary to conventional diagnostic methods, as well as for the localization of active disease after chemotherapy and monitoring for the presence of recurrent disease. Nevertheless, prospective studies in a large number of patients should be undertaken in order to further evaluate the diagnostic contribution of this approach.

show abstract

Section: Radioimmunodetectio N Of Ovarian Cancersupporting

confidence: 89%

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Kalofonos

2001

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…Although studies have revealed that CA-125 is not tumor specific, , the strategy of combining multiple tumor markers found in serum has been shown to facilitate the detection of early stage tumors and accurately identify tumor recurrence. , Unfortunately, serum markers cannot be used to determine tumor volume or location, which is critical information in the clinical management of cancer patients. Antibodies which recognize glycoprotein markers have been used for preclincal positron emission tomography (PET) studies as well as clinical studies with single photon emission computed tomography (SPECT) probes and show selective binding to tumors over healthy tissues. − In the current study, the novel mAb H6-11 originally identified using the human colon adenocarcinoma cell line, NSY42129, was evaluated against a panel of 40 human prostate carcinoma samples, 8 samples of normal prostate tissue, and 1 hepatic carcinoma sample; the expression of mAb H6-11 binding epitope in the PC-3 prostate cancer cell line was also examined. We found that mAb H6-11 recognizes a β- N -acetylglucoside group.…”

Section: Introductionmentioning

confidence: 99%

Preclinical Evaluation of the Novel Monoclonal Antibody H6-11 for Prostate Cancer Imaging

Jin

Padakanti

et al. 2013

Mol. Pharmaceutics

View full text Add to dashboard Cite

The biological properties of the novel monoclonal antibody (mAb) H6-11 and its potential utility for oncological imaging studies were evaluated using in vitro and in vivo assays. Immunoreactivity of H6-11 to the human prostate cancer PC-3 cell line and solid tumor xenografts was initially demonstrated using immunofluorescence staining; the specificity of H6-11 for prostate cancer was further evaluated using a commercial array of human prostate cancer and normal tissue samples (n = 49) in which H6-11 detected 95% of prostate adenocarcinomas. The Kd value of 61.7 ± 30 nM was determined using 125I-labeled H6-11. Glycosylation analysis suggested the antigenic epitope of the glycan is an O-linked β-N-acetylglucoside (O-GlcNAc) group. Imaging studies of PC-3 tumor-bearing mice were performed using both optical imaging with NIR fluorescent dye-labeled H6-11 and microPET imaging with 89Zr-labeled H6-11. These in vivo studies revealed that the labeled probes accumulated in PC-3 tumors 48–72 h postinjection, although significant retention in liver was also observed. By 120 h postinjection, the tumors were still evident, although the liver showed significant clearance. These studies suggest that the mAb H6-11 may be a useful tool to detect prostate cancer in vitro and in vivo.

show abstract

“…A recent technique now allows 99m Tc labeling of antibodies and leads to increased labeling efficiency and in vivo stability [11,12]. Lieberman et al [13] reported that with 99m Tclabeled Mab it is possible to detect all patients who have cancer. Sirisriro et al [14] demonstrated successfully imaged colorectal carcinoma with 99m Tc with high specificity and sensitivities.…”

Section: Introductionmentioning

confidence: 99%